ACER Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2023-04-14 | 2021 | Chris Schelling President and Chief Executive Officer | 436,000 | 0 | 0 | 0 | 0 | 552,236 |
| 2023-04-14 | 2022 | Harry S. Palmin Chief Financial Officer | 392,400 | 152,960 | 0 | 0 | 0 | 592,593 |
| 2023-04-14 | 2022 | Chris Schelling President and Chief Executive Officer | 500,015 | 239,800 | 0 | 0 | 0 | 834,230 |
| 2023-04-14 | 2021 | Harry S. Palmin Chief Financial Officer | 382,400 | 0 | 0 | 0 | 0 | 556,754 |
| 2023-04-14 | 2022 | Adrian Quartel | 365,064 | 0 | 0 | 0 | 0 | 801,044 |
| 2022-04-15 | 2020 | Chris Schelling President and Chief Executive Officer | 436,000 | 239,800 | 0 | 0 | 0 | 675,800 |
| 2022-04-15 | 2021 | Jefferson E. Davis | 326,667 | 0 | 0 | 0 | 0 | 634,797 |
| 2022-04-15 | 2020 | Harry S. Palmin Chief Operating Officer and Chief Financial Officer | 382,400 | 152,960 | 0 | 0 | 0 | 535,360 |
| 2022-04-15 | 2021 | Harry S. Palmin Chief Operating Officer and Chief Financial Officer | 382,400 | 0 | 0 | 0 | 0 | 556,754 |
| 2022-04-15 | 2021 | Chris Schelling President and Chief Executive Officer | 436,000 | 0 | 0 | 0 | 0 | 552,236 |
| 2021-04-16 | 2019 | Chris Schelling President and Chief Executive Officer | 436,000 | 0 | 0 | 0 | 0 | 1,467,211 |
| 2021-04-16 | 2020 | Donald R. Joseph | 350,200 | 140,080 | 0 | 0 | 0 | 490,280 |
| 2021-04-16 | 2019 | Harry S. Palmin Chief Operating Officer and Chief Financial Officer | 382,400 | 0 | 0 | 0 | 0 | 844,441 |
| 2021-04-16 | 2020 | Harry S. Palmin Chief Operating Officer and Chief Financial Officer | 382,400 | 152,960 | 0 | 0 | 0 | 535,360 |
| 2021-04-16 | 2020 | Chris Schelling President and Chief Executive Officer | 436,000 | 239,800 | 0 | 0 | 0 | 675,800 |
| 2020-10-14 | 2018 | Chris Schelling President and Chief Executive Officer | 400,000 | 150,000 | 0 | 0 | 0 | 550,000 |
| 2020-10-14 | 2018 | Harry S. Palmin Chief Operating Officer and Chief Financial Officer | 340,000 | 89,250 | 0 | 0 | 0 | 429,250 |
| 2020-10-14 | 2019 | Harry S. Palmin Chief Operating Officer and Chief Financial Officer | 382,400 | 0 | 0 | 0 | 0 | 844,441 |
| 2020-10-14 | 2018 | William T. Andrews, M.D., FACP Former Chief Medical Officer | 400,000 | 105,000 | 0 | 0 | 0 | 505,000 |
| 2020-10-14 | 2019 | William T. Andrews, M.D., FACP Former Chief Medical Officer | 412,000 | 0 | 212,400 | 0 | 0 | 1,086,441 |
| 2020-10-14 | 2019 | Chris Schelling President and Chief Executive Officer | 436,000 | 0 | 0 | 0 | 0 | 1,467,211 |
| 2019-04-12 | 2017 | William T. Andrews, M.D., FACP Chief Medical Officer | 100,000 | 40,000 | 0 | 0 | 0 | 1,018,921 |
| 2019-04-12 | 2017 | Harry Palmin Chief Operating Officer and Chief Financial Officer | 99,167 | 0 | 0 | 0 | 0 | 693,318 |
| 2019-04-12 | 2018 | Harry Palmin Chief Operating Officer and Chief Financial Officer | 340,000 | 89,250 | 0 | 0 | 0 | 429,250 |
| 2019-04-12 | 2018 | William T. Andrews, M.D., FACP Chief Medical Officer | 400,000 | 105,000 | 0 | 0 | 0 | 505,000 |
| 2019-04-12 | 2017 | Chris Schelling President and Chief Executive Officer | 116,667 | 0 | 0 | 0 | 0 | 585,458 |
| 2019-04-12 | 2018 | Chris Schelling President and Chief Executive Officer | 400,000 | 150,000 | 0 | 0 | 0 | 550,000 |
| 2018-04-09 | 2017 | Chris Schelling | 116,667 | 0 | 0 | 0 | 0 | 585,458 |
| 2018-04-09 | 2016 | Neil K. Warma Former President, Chief Executive Officer and Acting Chief Financial Officer (Opexa Therapeutics, Inc.) | 416,625 | 0 | 0 | 0 | 0 | 618,471 |
| 2018-04-09 | 2017 | Neil K. Warma Former President, Chief Executive Officer and Acting Chief Financial Officer (Opexa Therapeutics, Inc.) | 301,147 | 0 | 0 | 0 | 889,307 | 1,190,454 |
| 2018-04-09 | 2017 | Harry Palmin | 99,167 | 0 | 0 | 0 | 0 | 693,318 |
| 2018-04-09 | 2017 | William T. Andrews, M.D., FACP | 100,000 | 40,000 | 0 | 0 | 0 | 1,018,921 |
| 2016-04-11 | 2014 | Neil K. Warma President and Chief Executive Officer | 406,464 | 172,747 | 94,181 | 0 | 0 | 1,810,749 |
| 2016-04-11 | 2014 | Karthik Radhakrishnan Former Chief Financial Officer | 246,000 | 71,033 | 30,319 | 0 | 0 | 579,769 |
| 2016-04-11 | 2015 | Karthik Radhakrishnan Former Chief Financial Officer | 271,250 | 0 | 0 | 0 | 0 | 309,630 |
| 2016-04-11 | 2015 | Don Healey, Ph.D. | 266,240 | 0 | 0 | 0 | 0 | 312,296 |
| 2016-04-11 | 2015 | Neil K. Warma President and Chief Executive Officer | 416,625 | 0 | 0 | 0 | 0 | 508,737 |
| 2015-07-23 | 2013 | Neil K. Warma President and Chief Executive Officer | 396,550 | 94,180 | 53,713 | 0 | 0 | 636,767 |
| 2015-07-23 | 2013 | Donna R. Rill Chief Development Officer | 240,006 | 22,500 | 37,750 | 0 | 0 | 334,548 |
| 2015-07-23 | 2014 | Donna R. Rill Chief Development Officer | 246,000 | 72,109 | 22,500 | 0 | 0 | 573,026 |
| 2015-07-23 | 2013 | Karthik Radhakrishnan Chief Financial Officer | 180,925 | 30,319 | 0 | 0 | 20,099 | 516,569 |
| 2015-07-23 | 2014 | Karthik Radhakrishnan Chief Financial Officer | 246,000 | 71,033 | 30,319 | 0 | 0 | 579,769 |
| 2015-07-23 | 2014 | Neil K. Warma President and Chief Executive Officer | 406,464 | 172,747 | 94,181 | 0 | 0 | 1,810,749 |
| 2014-05-12 | 2013 | Neil K. Warma President and Chief Executive Officer | 396,550 | 94,180 | 53,713 | 0 | 0 | 636,767 |
| 2014-05-12 | 2012 | Donna R. Rill Chief Development Officer | 220,000 | 15,000 | 0 | 0 | 250 | 389,402 |
| 2014-05-12 | 2013 | Karthik Radhakrishnan | 180,925 | 30,319 | 0 | 0 | 20,099 | 516,659 |
| 2014-05-12 | 2012 | Neil K. Warma President and Chief Executive Officer | 396,550 | 50,000 | 0 | 0 | 100 | 1,135,334 |
| 2014-05-12 | 2013 | Donna R. Rill Chief Development Officer | 240,006 | 44,500 | 37,750 | 0 | 0 | 356,548 |
| 2013-10-03 | 2012 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 220,000 | 10,000 | 0 | 0 | 50 | 384,202 |
| 2013-10-03 | 2012 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 396,550 | 50,000 | 0 | 0 | 100 | 1,135,334 |
| 2013-10-03 | 2011 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 385,000 | 50,000 | 0 | 0 | 0 | 550,051 |
| 2013-10-03 | 2012 | Donna R. Rill Senior Vice President of Operations and Quality Systems | 220,000 | 15,000 | 0 | 0 | 250 | 389,402 |
| 2013-10-03 | 2011 | Donna R. Rill Senior Vice President of Operations and Quality Systems | 200,000 | 15,000 | 0 | 0 | 0 | 253,350 |
| 2013-10-03 | 2011 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 200,000 | 15,000 | 0 | 0 | 0 | 253,350 |
| 2012-10-09 | 2011 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 385,000 | 50,000 | 0 | 0 | 0 | 550,051 |
| 2012-10-09 | 2010 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 362,083 | 50,000 | 0 | 0 | 0 | 412,083 |
| 2012-10-09 | 2011 | Donna R. Rill Senior Vice President of Operations and Quality Systems | 200,000 | 15,000 | 0 | 0 | 0 | 253,350 |
| 2012-10-09 | 2010 | Donna R. Rill Senior Vice President of Operations and Quality Systems | 208,000 | 0 | 0 | 0 | 0 | 208,000 |
| 2012-10-09 | 2011 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 200,000 | 15,000 | 0 | 0 | 0 | 253,350 |
| 2012-10-09 | 2010 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 200,000 | 0 | 0 | 0 | 0 | 200,000 |
| 2011-09-22 | 2010 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 200,000 | 25,000 | 0 | 0 | 0 | 225,000 |
| 2011-09-22 | 2009 | Donna R. Rill Senior Vice President of Operations and Quality Systems | 197,963 | 0 | 0 | 0 | 0 | 311,833 |
| 2011-09-22 | 2010 | Donna R. Rill Senior Vice President of Operations and Quality Systems | 208,000 | 25,000 | 0 | 0 | 0 | 233,000 |
| 2011-09-22 | 2009 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 312,083 | 142,500 | 0 | 0 | 0 | 689,700 |
| 2011-09-22 | 2010 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 362,083 | 50,000 | 0 | 0 | 0 | 412,083 |
| 2011-09-22 | 2009 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 23,590 | 0 | 0 | 0 | 0 | 125,030 |
| 2010-09-14 | 2009 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 312,083 | 142,500 | 0 | 0 | 0 | 689,700 |
| 2010-09-14 | 2008 | Donna R. Rill Senior Vice President of Operations | 141,886 | 0 | 0 | 0 | 0 | 252,288 |
| 2010-09-14 | 2008 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 0 | 0 | 0 | 0 | 0 | 0 |
| 2010-09-14 | 2009 | Jaye L. Thompson, Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs | 23,590 | 0 | 0 | 0 | 0 | 125,030 |
| 2010-09-14 | 2009 | Donna R. Rill Senior Vice President of Operations | 197,963 | 0 | 0 | 0 | 0 | 311,833 |
| 2010-09-14 | 2008 | Neil K. Warma President, Chief Executive Officer, Acting Chief Financial Officer | 195,100 | 0 | 0 | 0 | 62,487 | 330,456 |
| 2009-10-02 | 2007 | Jim C. Williams Chief Operating Officer | 225,750 | 0 | 0 | 0 | 0 | 674,774 |
| 2009-10-02 | 2007 | Donna R. Rill Senior V.P. of Operations | 137,940 | 10,000 | 0 | 0 | 0 | 382,538 |
| 2009-10-02 | 2008 | Donna R. Rill Senior V.P. of Operations | 141,886 | 0 | 0 | 0 | 0 | 252,288 |
| 2009-10-02 | 2007 | Lynne Hohlfeld CFO and Secretary | 175,000 | 0 | 0 | 0 | 0 | 277,700 |
| 2009-10-02 | 2008 | Lynne Hohlfeld CFO and Secretary | 175,000 | 0 | 0 | 0 | 0 | 310,135 |
| 2009-10-02 | 2008 | Jim C. Williams Chief Operating Officer | 225,750 | 0 | 0 | 0 | 0 | 387,216 |
| 2009-10-02 | 2007 | David B. McWilliams CEO, President, Director | 275,000 | 0 | 0 | 0 | 0 | 686,807 |
| 2009-10-02 | 2008 | David B. McWilliams CEO, President, Director | 148,959 | 0 | 0 | 0 | 0 | 849,018 |
| 2009-10-02 | 2007 | Neil K. Warma CEO, President, Director | 0 | 0 | 0 | 0 | 0 | 0 |
| 2009-10-02 | 2008 | Neil K. Warma CEO, President, Director | 195,100 | 0 | 0 | 0 | 62,487 | 330,456 |
| 2008-08-21 | 2006 | David B. McWilliams CEO, President, Director | 264,497 | 0 | 0 | 0 | 0 | 761,874 |
| 2008-08-21 | 2007 | David B. McWilliams CEO, President, Director | 275,000 | 0 | 0 | 0 | 0 | 686,807 |
| 2008-08-21 | 2006 | Jim C. Williams Chief Operating Officer | 227,094 | 0 | 0 | 0 | 0 | 628,668 |
| 2008-08-21 | 2007 | Lynne Hohlfeld CFO and Secretary | 175,000 | 0 | 0 | 0 | 0 | 277,700 |
| 2008-08-21 | 2006 | Lynne Hohlfeld CFO and Secretary | 131,250 | 0 | 0 | 0 | 0 | 172,089 |
| 2008-08-21 | 2007 | Jim C. Williams Chief Operating Officer | 225,750 | 0 | 0 | 0 | 0 | 674,774 |
| 2008-08-21 | 2007 | Donna R. Rill Vice President of Operations | 137,940 | 10,000 | 0 | 0 | 0 | 382,538 |
| 2008-08-21 | 2006 | Donna R. Rill Vice President of Operations | 133,500 | 0 | 0 | 0 | 0 | 330,090 |
| 2007-04-27 | 2006 | Lynne Hohlfeld | 131,250 | 0 | 0 | 0 | 0 | 172,089 |
| 2007-04-27 | 2006 | C. William Rouse | 90,000 | 0 | 0 | 0 | 0 | 940,819 |
| 2007-04-27 | 2006 | David B. McWilliams | 264,497 | 0 | 0 | 0 | 0 | 761,874 |
| 2006-05-15 | 2004 | David B. McWilliams | 83,000 | 0 | 0 | 0 | 0 | 83,000 |
| 2006-05-15 | 2005 | David B. McWilliams | 250,000 | 0 | 0 | 0 | 0 | 250,000 |
| 2006-05-15 | 2003 | C. William Rouse | 0 | 0 | 0 | 0 | 0 | 0 |
| 2006-05-15 | 2004 | C. William Rouse | 77,500 | 0 | 0 | 0 | 0 | 77,500 |
| 2006-05-15 | 2005 | C. William Rouse | 180,000 | 0 | 0 | 0 | 0 | 180,000 |
| 2006-05-15 | 2003 | David B. McWilliams | 0 | 0 | 0 | 0 | 0 | 0 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
